Advertisement

Topics

ASH 2017: Regeneron to Share Clinical Progress of REGN1979 and Cemiplimab in B-Cell Lymphomas

15:38 EST 8 Nov 2017 | Drug Discovery Development

Both studies enrolled patients with B-cell non-Hodgkin lymphoma or Hodgkin lymphoma previously treated with at least one prior therapy and for whom no standard-of-care options exist.
Contributed Author: 
Regeneron

Original Article: ASH 2017: Regeneron to Share Clinical Progress of REGN1979 and Cemiplimab in B-Cell Lymphomas

NEXT ARTICLE

More From BioPortfolio on "ASH 2017: Regeneron to Share Clinical Progress of REGN1979 and Cemiplimab in B-Cell Lymphomas"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Hodgkin lymphoma
Hodgkin Lymphoma is a  disorder caused by malignant proliferation of lymphocytes, which contain characteristic mirror-image nuclei (Reed-Sternburg cells). The resulting lymphadenopathy can be limited to a single lymph node region (Stage 1) or spread...